日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR

对维贝格隆治疗膀胱过度活动症患者症状缓解意义的解读：来自EMPOWUR的分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-021-01972-8
Frankel, Jeffrey; Staskin, David; Varano, Susann; Kennelly, Michael; Newman, Diane K; Rosenberg, Matt T; Jankowich, Rachael A; Shortino, Denise; Mudd, Paul N Jr; Girman, Cynthia J
发表日期：2022
文献求助 收藏

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial

维贝格隆治疗女性肠易激综合征的疗效和安全性：一项随机、双盲、安慰剂对照的II期试验结果

期刊:Neurogastroenterology and Motility
影响因子:2.9
doi:10.1111/nmo.14448
Lacy, Brian E; King, Jennifer; Shortino, Denise; Schaumburg, Chris; Haag-Molkenteller, Cornelia; Chey, William D
肠易激综合征
发表日期：2022
文献求助 收藏

Long-term efficacy and safety of vibegron versus mirabegron and anticholinergics for overactive bladder: a systematic review and network meta-analysis

维贝格隆与米拉贝隆和抗胆碱能药物治疗膀胱过度活动症的长期疗效和安全性：系统评价和网络荟萃分析

期刊:Drugs in Context
影响因子:2.8
doi:10.7573/dic.2022-4-2
Kennelly, Michael; Wielage, Ronald; Shortino, Denise; Thomas, Elizabeth; Mudd, Paul N Jr
发表日期：2022
文献求助 收藏

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial

维贝格隆治疗干性膀胱过度活动症和湿性膀胱过度活动症患者：EMPOWUR试验的亚组分析

期刊:International Journal of Clinical Practice
影响因子:2.4
doi:10.1155/2022/6475014
Staskin, David; Frankel, Jeffrey; Varano, Susann; Kennelly, Michael; Newman, Diane K; Rosenberg, Matt T; Shortino, Denise D; Jankowich, Rachael A; Mudd, Paul N Jr
发表日期：2022
文献求助 收藏

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison

维贝格隆和米拉贝格隆治疗膀胱过度活动症的疗效：系统性文献综述和间接治疗比较

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-021-01902-8
Kennelly, Michael J; Rhodes, Thomas; Girman, Cynthia J; Thomas, Elizabeth; Shortino, Denise; Mudd, Paul N Jr
发表日期：2021
文献求助 收藏

Efficacy and Safety of Once-Daily Vibegron for Treatment of Overactive Bladder in Patients Aged ≥65 and ≥75 Years: Subpopulation Analysis from the EMPOWUR Randomized, International, Phase III Study

每日一次服用维贝格隆治疗≥65岁和≥75岁患者膀胱过度活动症的疗效和安全性：EMPOWUR随机、国际、III期研究的亚组分析

期刊:Drugs & Aging
影响因子:3.8
doi:10.1007/s40266-020-00829-z
Varano, Susann; Staskin, David; Frankel, Jeffrey; Shortino, Denise; Jankowich, Rachael; Mudd, Paul N Jr
发表日期：2021
文献求助 收藏

Vibegron improves quality-of-life measures in patients with overactive bladder: Patient-reported outcomes from the EMPOWUR study

维贝格隆改善膀胱过度活动症患者的生活质量：EMPOWUR 研究的患者报告结果

期刊:International Journal of Clinical Practice
影响因子:2.4
doi:10.1111/ijcp.13937
Frankel, Jeffrey; Varano, Susann; Staskin, David; Shortino, Denise; Jankowich, Rachael; Mudd, Paul N Jr
发表日期：2021
文献求助 收藏

Population Pharmacokinetic/Pharmacodynamic Analysis of Intravenous Zanamivir in Healthy Adults and Hospitalized Adult and Pediatric Subjects With Influenza

健康成人和住院成人及儿童流感患者静脉注射扎那米韦的群体药代动力学/药效学分析

期刊:Cts-Clinical and Translational Science
影响因子:2.8
doi:10.1111/cts.12697
Zuo, Peiying; Collins, Jon; Okour, Malek; Barth, Aline; Shortino, Denise; Yates, Phillip; Roberts, Grace; Watson, Helen A; Peppercorn, Amanda; Hossain, Mohammad
微生物学
流感
发表日期：2020
文献求助 收藏

Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

2000年至2009年美国未接受抗逆转录病毒治疗的HIV-1感染者中，携带耐药相关突变的HIV-1病毒流行率的变化

期刊:Aids Research and Human Retroviruses
影响因子:1.1
doi:10.1089/AID.2017.0295
Ross, Lisa L; Shortino, Denise; Shaefer, Mark S
HIV
炎症/感染
微生物学
发表日期：2018
文献求助 收藏